Codexis

行业

工业化学

主题

酶与生物催化

角色

生产商 — “…proteins for pharmaceutical manufacturing and diagnostic applications. Founded in 2002, the company utilizes i…”

为何属于生物经济

Codexis 是生物技术公司，为医药生物催化和 RNA 制造应用设计酶。

尚未被列为已评级方案的供应商。

近期新闻 5

由自动检索获得；摘要为机器生成的英文。标题含公司名称，或摘要以该公司为主体——引用前请核对原文。

• 2026-09-28 Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA :: … ir.codexis.com
  Codexis announces a collaboration with a leading siRNA drug innovator to use its ECO Synthesis platform for enzymatic, stereo-defined fragment synthesis and ligation into final siRNA duplexes, comparing with solid-phase methods to assess purity and quality. This underscores …
• 2026-08-12 Codexis Reports Second Quarter 2026 Financial Results - BioSpace biospace.com
  Codexis reported Q2 2026 revenue of $14.9 million, reiterated full-year guidance (revenues $72–$76 million; gross margin high‑60s%), and healthy cash runway (pro forma ~$80 million after a July $25 million equity raise). The company highlighted progress commercialization of its …
• 2026-08-03 Codexis Appoints David Butler, PhD, to Strategic Advisory globenewswire.com
  Codexis is expanding its strategic leadership by adding David Butler, PhD, to its Strategic Advisory Board, signaling a focus on advancing siRNA therapeutics and industrializing its enzymatic technology for scalable manufacturing. The company also acknowledges Carole Cobb’s …
• 2026-08-03 Codexis Appoints David Butler, PhD, to Strategic Advisory globenewswire.com
  Codexis is expanding its strategic leadership by adding David Butler, PhD, to its Strategic Advisory Board to bolster its growth and expertise in siRNA therapeutics and scalable enzymatic manufacturing, while thanking Carole Cobb for her contributions as she steps down. The …
• 2026-07-24 Codexis Prices $23.1M Public Offering | GenomeWeb genomeweb.com
  Codexis is raising about $23.1 million from a public stock offering at $1.50 per share (approximately 16.7 million shares with an option for up to 2.5 million more), to fund working capital, R&D, and general corporate purposes; the company also reports solid Q1 revenue growth …

同类企业

Genencor · Amyris · EDT-Enzymatic Deinking Technologies, LLC · Jeneil Biotech, Inc. · Dyadic Applied BioSolutions · Yzymes · Protein Evolution · Mascoma LLC

注册编号

• I.R.S. Employer Identification No.: 71-0872999

融资

• 最近一轮: Post ipo equity · 2026-07-01
• 累计融资: US$ 229.3 M

来自自动化调研（公司网站、公告、商业企业数据库），未经人工核对。注册编号请以官方登记为准。